Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo

Brain Research

Volumn 1222, Issue , 2008, Pages 222-229

  Pan, Tianhong ^a   Zhu, Wen ^a   Zhao, Hongru ^a   Deng, Hao ^a   Xie, Wenjie ^a   Jankovic, Joseph ^b   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Parkinson's Disease Center   (United States)

Author keywords

Lactacystin; Nurr1; Parkinson's disease; SH SY5Y cell; Ubiquitin proteasome system

Indexed keywords

CASPASE 3; DOPAMINE; LACTACYSTIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR RECEPTOR RELATED FACTOR 1; PROTEASOME; PROTEIN BCL 2; PROTEIN P53; SMALL INTERFERING RNA; TYROSINE 3 MONOOXYGENASE; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MEDIAL FOREBRAIN BUNDLE; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; SUBSTANTIA NIGRA;

ACETYLCYSTEINE; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BRAIN INJURIES; CAUSALITY; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOPAMINE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, KNOCKOUT; NEUROBLASTOMA; NEURONS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION; TYROSINE 3-MONOOXYGENASE;

MUS;

EID: 46749098229     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.05.022     Document Type: Article

References (40)

1. Backman C., You Z.B., Perlmann T., and Hoffer B.J. Elevated locomotor activity without altered striatal dopamine contents in Nurr1 heterozygous mice after acute exposure to methamphetamine. Behav. Brain Res. 143 (2003) 95-100
2. Betarbet R., Sherer T.B., and Greenamyre J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol. 191 Suppl 1 (2005) S17-S27
3. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H.J., Wu D.C., Kordower J.H., Petrucelli L., and Przedborski S. Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 60 (2006) 260-264
4. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003) 197-211
5. Buervenich S., Carmine A., Arvidsson M., Xiang F., Zhang Z., Sydow O., Jonsson E.G., Sedvall G.C., Leonard S., Ross R.G., Freedman R., Chowdari K.V., Nimgaonkar V.L., Perlmann T., Anvret M., and Olson L. NURR1 mutations in cases of schizophrenia and manic-depressive disorder. Am. J. Med. Genet. 96 (2000) 808-813
6. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol 41 (2001) 237-260
7. Chen Y.H., Tsai M.T., Shaw C.K., and Chen C.H. Mutation analysis of the human NR4A2 gene, an essential gene for midbrain dopaminergic neurogenesis, in schizophrenic patients. Am. J. Med. Genet. 105 (2001) 753-757
8. Chu Y., Le W., Kompoliti K., Jankovic J., Mufson E.J., and Kordower J.H. Nurr1 in Parkinson's disease and related disorders. J. Comp. Neurol 494 (2005) 495-514
9. Dykxhoorn D.M., Novina C.D., and Sharp P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev., Mol. Cell Biol. 4 (2003) 457-467
10. Eells J.B., Yeung S.K., and Nikodem V.M. Dopamine neurons heterozygous for the Nurr1-Null allele have reduced survival in vitro. Neurosci. Res. Comm 30 (2002) 173-183
11. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Busceti C.L., Ruffoli R., Soldani P., Ruggieri S., Alessandri M.G., and Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci 23 (2003) 8955-8966
12. Grimes D.A., Han F., Panisset M., Racacho L., Xiao F., Zou R., Westaff K., and Bulman D.E. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov. Disord 21 (2006) 906-909
13. Imam S.Z., Jankovic J., Ali S.F., Skinner J.T., Xie W., Conneely O.M., and Le W.D. Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice. FASEB J. 19 (2005) 1441-1450
14. Jankovic J., Chen S., and Le W. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog. Neurobiol. 77 (2005) 128-138
15. Jenner P., and Olanow C.W. The pathogenesis of cell death in Parkinson's disease. Neurology 66 (2006) S24-S36
16. Jiang C., Wan X., He Y., Pan T., Jankovic J., and Le W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp. Neurol. 191 (2005) 154-162
17. Kordower J.H., Kanaan N.M., Chu Y., Babu R.S., Stansell III J., Terpstra B.T., Sortwell C.E., Steece-Collier K., and Collier T.J. Failure of proteasome inhibitors to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 60 (2006) 264-268
18. Law S.W., Conneely O.M., DeMayo F.J., and Malley B.W. Identification of a new brain-specific transcription factor, NURR1. Mol. Endocrinol. 16 (1992) 2129-2135
19. 3H-GBR12935 to measure dopaminergic nerve terminal growth into rat striatum. Dev. Brain Res. 67 (1992) 375-377
20. Le W.D., Conneely O.M., and He Y. Reduced NURR1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 73 (1999) 2218-2221
21. Le W.D., Xu P., Jankovic J., Jiang H., Appel S.H., Smith R.G., and Vassilatis D.K. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33 (2003) 85-89
22. Leenders K.L. Disease process and drug treatments in Parkinson's disease. Eur. Neuropsychopharmacol. 12 (2002) 575-580
23. Lev N., Melamed E., and Offen D. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neurosci. Lett. 399 (2006) 27-32
24. Manning-Bog A.B., Reaney S.H., Chou V.P., Johnston L.C., McCormack A.L., Johnston J., Langston J.W., and Di Monte D.A. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 60 (2006) 256-260
25. McNaught K.S., Björklund L.M., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13 (2002) 1437-1441
26. McNaught K.S., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179 (2003) 38-46
27. McNaught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56 (2004) 149-162
28. Miwa H., Kubo T., Suzuki A., Nishi K., and Kondo T. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci. Lett 380 (2005) 93-98
29. p53. Nair V.D., McNaught K.S., González-Maeso J., Sealfon S.C., and Olanow C.W. mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 281 (2006) 39550-39560
30. Qiu J.H., Asai A., Chi S., Saito N., Hamada H., and Kirino T. Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical Neurons. J. Neurosci. 20 (2000) 259-265
31. Saucedo-Cardenas O., and Conneely O.M. Comparative distribution of Nurr1 and Nur77 nuclear receptors in the mouse central nervous system. J. Mol. Neurosci. 7 (1996) 51-63
32. Saucedo-Cardenas O., Quintana-Hau J.D., Le W.D., Smidt M.P., Cox J.J., Mayo F.D., Burbach J.P.H., and Conneely O.M. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4013-4018
33. Schapira A.H. Etiology of Parkinson's disease. Neurology 66 (2006) S10-S23
34. Smith K.M., Bauer L., Fischer M., Barkley R., and Navia B.A. Identification and characterization of human NR4A2 polymorphisms in attention deficit hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133 (2005) 57-63
35. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res. Brain Res. Rev. 31 (2000) 320-329
36. Wallen A., Zetterstrom R.H., Solomin L., Arvidsson M., Olson L., and Perlmann T. Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice. Exp. Cell Res. 253 (1999) 737-746
37. Xu P.Y., Liang R., Jankovic J., Hunter C., Zeng Y.X., Ashizawa T., Lai D., and Le W.D. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology 58 (2002) 881-884
38. Zetterstrom R.H., Williams R., Perlmann T., and Olson L. Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res. Mol. Brain Res. 41 (1996) 111-120
39. Zetterström R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., and Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 276 (1997) 248-250
40. Zhang X., Xie W., Qu S., Pan T., Wang X., and Le W. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun. 333 (2005) 544-549